Harmony BiosciencesHRMY
HRMY
About: Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.
Employees: 246
0
Funds holding %
of 6,831 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
119% more call options, than puts
Call options by funds: $4.39M | Put options by funds: $2M
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
29% more capital invested
Capital invested by funds: $1.54B [Q2] → $2B (+$455M) [Q3]
20% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 6 (+1) [Q3]
6% more funds holding
Funds holding: 218 [Q2] → 231 (+13) [Q3]
2.15% less ownership
Funds ownership: 90.05% [Q2] → 87.91% (-2.15%) [Q3]
21% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 87
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
33%
upside
Avg. target
$64
63%
upside
High target
$75
92%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 40% 1-year accuracy 70 / 175 met price target | 92%upside $75 | Buy Reiterated | 27 Jan 2025 |
Needham Ami Fadia 51% 1-year accuracy 84 / 165 met price target | 33%upside $52 | Buy Reiterated | 13 Jan 2025 |
Financial journalist opinion
Based on 10 articles about HRMY published over the past 30 days
Positive
Zacks Investment Research
4 days ago
Wall Street Analysts Predict a 28.98% Upside in Harmony Biosciences (HRMY): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 29% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
5 days ago
HRMY vs. RGEN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two stocks presents investors with the better value opportunity right now?
Positive
Seeking Alpha
1 week ago
Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech
Harmony Biosciences Holdings, Inc.'s Wakix, a first-in-class drug for narcolepsy, has shown strong revenue growth and recent label expansion to pediatric patients, with good future growth potential. Despite past challenges, including a short attack and a failed Phase 3 study, Harmony's stock has rebounded, supported by solid financials and strategic product extensions. Harmony's diversified pipeline, including new indications for pitolisant / Wakix, and other Phase 3 candidates, positions it for significant revenue growth and reduced single-asset risk.
Positive
Zacks Investment Research
1 week ago
4 High Earnings Yield Value Stocks to Buy as Trump Resumes Presidency
Unlock your portfolio value with high earnings yield value stocks like HRMY, NGVT, GPOR and PBI.
Positive
Zacks Investment Research
2 weeks ago
Should Value Investors Buy Harmony Biosciences (HRMY) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
Why Harmony Biosciences (HRMY) Might be Well Poised for a Surge
Harmony Biosciences (HRMY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Positive
Zacks Investment Research
2 weeks ago
How Much Upside is Left in Harmony Biosciences (HRMY)? Wall Street Analysts Think 39.48%
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 39.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
3 weeks ago
HRMY or RGEN: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two companies is the best option for those looking for undervalued stocks?
Positive
Investors Business Daily
3 weeks ago
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports. The post BridgeBio, ARS Pharma, Harmony Bio Shine At JPM.
Neutral
Business Wire
3 weeks ago
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong preliminary, unaudited net product revenues for Q4 and full year 2024 of $201 million and $714 million, respectively. Building on this performance, the company is well positioned for a catalyst-rich 2025, with value-creating milestones anticipated every quarter. Harmony will be highlighting its catalysts for 2025 and other key milestones during its presentation at the 43rd Annual J.P.
Charts implemented using Lightweight Charts™